** Citigroup starts coverage of Kymera Therapeutics' KYMR.O shares with "buy/high risk" rating and $52 PT, a ~48% upside to stock's last close
** Brokerage says company's targeted protein degradation technology offers "first-in-class" approaches in the treatment of various inflammatory and immunological diseases
** Company's atopic dermatitis drug KT-621 has shown "robust preclinical data" with potential to achieve "comparable or superior efficacy" to Regeneron REGN.O and Sanofi's SASY.PA Dupixent, Citigroup says
** Kymera's inflammatory skin disease drug KT-474 has shown promising data in clinical trials, particularly in hidradenitis suppurativa, where it demonstrated a "remarkable ~60% reduction in symptoms", positioning it as a potential "best-in-class" therapy - brokerage
** Brokerage estimates company's revenue to reach $1 bln by 2032, with each additional $500 bln in sales potentially adding $20 to the stock price
** Kymera's shares rose 58.7% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。